Demographics

View past meeting statistics and demographic information for the Annual Meeting.

2018 Registration Numbers

  • Total—40,700
  • Professionals—33,100
  • Exhibitors—5,700
  • Spouse, Guest, Media—1,950
  • Domestic Attendees—54%
  • International Attendees—46%

Top 10 Countries in Attendance in 2018

  • United States—18,008
  • Japan—1,445
  • China—1,231
  • Germany—1,187
  • France—1,185
  • United Kingdom—1,093
  • Canada—809
  • Brazil—790
  • Switzerland—638
  • Spain—558

Primary Professional Role in 2018

Primary Professional Role Percentage of Attendees Who Responded
Medical Oncologist 14%
Physician 12%
Researcher 7%
Clinical Oncologist 5%
Marketing Representative 4%
Consultant 3%
Hematologic Oncologist 2%
Pharmacist 2%
Business Administrator 2%
Oncology Fellow Resident 2%
Medical Science Liaison 2%
Pharmaceutical Sales Representative 2%

Attendees were allowed to choose only one answer. Responded— 31,668 (96%). No Response—1432 (4%). Total—33,100             

Board Certification or International Equivalent in 2018

Board Certification or International Equivalent Percentage of Attendees Who Responded
Medical Oncology 32%
Internal Medicine 16%
Hematology 12%
Clinical Informatics 3%
Other 3%
Surgical Oncology 3%
Gynecologic Oncology 3%
Radiation Oncology 3%
Gastroenterology 2%
Pediatrics Hematology-Oncology 2%
Pathology 2%
General Surgery 1%
Obstetrics and Gynecology 1%
Pediatrics 1%
Urology / Urologic Oncology 1%
Neurology 1%
Dermatology 1%
Hospice and Palliative Medicine 1%
Diagnostic Radiology 1%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded—21,697 (66%). No Response—11,403 (34%). Totals—33,100 

Primary Interest in 2018

Primary Interest Percentage of Attendees Who Responded
Immunotherapy 38%
Clinical Trials 37%
Breast Cancer 32%
Lung Cancer 30%
Gastrointestinal (Colorectal Cancer) 19%
Developmental Therapeutics and Translational Research 19%
Tumor Biology 17%
Hematologic Malignancies - Lymphoma and CLL 14%
Gastrointestinal (Noncolorectal Cancer) 13%
Hematologic Malignancies - Leukemia, MDS, and Allotransplant 11%
Cancer Prevention, Genetics, and Epidemiology 11%
Genitourinary (Prostate) Cancer 11%
Melanoma / Skin Cancers 10%
Head and Neck Cancer 9%
Gynecologic Cancer 8%
Genitourinary (Nonprostate) Cancer 7%
Hematologic Malignancies - Plasma Cell Dyscrasia 6%
Professional Development 6%
Health Services Research, Clinical Informatics and Quality of Care 6%
Patient and Survivor Care 5%
Sarcoma  5%
Global Health 4%
Central Nervous System Tumors 4%
Care Delivery and Practice Management 4%
Pediatric Oncology 4%
Other 3%
Ethics 2%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded— 21,499 (65%). No Response—11,601 (35%). Totals—33,100